Ascletis Approved to Market Dual All-oral HCV Treatment in China
publication date: Jul 31, 2020
Ascletis Pharma of Hangzhou has been approved to market its dual-drug, all-oral HCV treatment in China for hepatitis C. The approval adds Ravidasvir (Asclevir®) to Danoprevir (Ganovo®), the first direct-acting anti-viral agent (DAA) developed by a China company for HCV, which was approved in China two years ago. Together, the RDV/DNV regimen demonstrated a cure rate of 99 % after a 12-week treatment in genotype 1 patients. Since its inception, Ascletis has been working toward an all-oral, interferon-free treatment for HCV with near 100% efficacy. More details...
Stock Symbol: (HK: 1672)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.